In the past week, ZLAB stock has gone down by -31.07%, with a monthly decline of -28.97% and a quarterly plunge of -2.71%. The volatility ratio for the week is 9.19%, and the volatility levels for the last 30 days are 5.75% for Zai Lab Limited ADR The simple moving average for the last 20 days is -28.13% for ZLAB stock, with a simple moving average of -2.39% for the last 200 days.
Is It Worth Investing in Zai Lab Limited ADR (NASDAQ: ZLAB) Right Now?
Additionally, the 36-month beta value for ZLAB is 1.13. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZLAB is 108.60M and currently, short sellers hold a 7.29% ratio of that float. The average trading volume of ZLAB on April 09, 2025 was 997.49K shares.
ZLAB) stock’s latest price update
The stock of Zai Lab Limited ADR (NASDAQ: ZLAB) has decreased by -7.24 when compared to last closing price of 27.07. Despite this, the company has experienced a -31.07% fall in its stock price over the last five trading sessions. businesswire.com reported 2025-03-26 that SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research.
Analysts’ Opinion of ZLAB
Many brokerage firms have already submitted their reports for ZLAB stocks, with Scotiabank repeating the rating for ZLAB by listing it as a “Sector Outperform.” The predicted price for ZLAB in the upcoming period, according to Scotiabank is $55 based on the research report published on March 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see ZLAB reach a price target of $36.10, previously predicting the price at $29. The rating they have provided for ZLAB stocks is “Neutral” according to the report published on March 03rd, 2025.
Morgan Stanley gave a rating of “Overweight” to ZLAB, setting the target price at $47.50 in the report published on December 14th of the previous year.
ZLAB Trading at -23.18% from the 50-Day Moving Average
After a stumble in the market that brought ZLAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.86% of loss for the given period.
Volatility was left at 5.75%, however, over the last 30 days, the volatility rate increased by 9.19%, as shares sank -28.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.61% lower at present.
During the last 5 trading sessions, ZLAB fell by -30.87%, which changed the moving average for the period of 200-days by +35.61% in comparison to the 20-day moving average, which settled at $34.94. In addition, Zai Lab Limited ADR saw -4.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZLAB starting from Smiley Joshua L, who sale 3,354 shares at the price of $33.11 back on Apr 04 ’25. After this action, Smiley Joshua L now owns 67,345 shares of Zai Lab Limited ADR, valued at $111,044 using the latest closing price.
Edmondson Frazor Titus III, the Chief Legal Officer of Zai Lab Limited ADR, sale 1,874 shares at $33.11 during a trade that took place back on Apr 04 ’25, which means that Edmondson Frazor Titus III is holding 30,375 shares at $62,044 based on the most recent closing price.
Stock Fundamentals for ZLAB
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.63 for the gross margin
The net margin for Zai Lab Limited ADR stands at -0.64. The total capital return value is set at -0.32. Equity return is now at value -31.41, with -23.14 for asset returns.
Based on Zai Lab Limited ADR (ZLAB), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -125.16.
Currently, EBITDA for the company is -242.99 million with net debt to EBITDA at 1.22. When we switch over and look at the enterprise to sales, we see a ratio of 7.27. The receivables turnover for the company is 4.46for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.51.
Conclusion
In conclusion, Zai Lab Limited ADR (ZLAB) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
